NCT00888901View on ClinicalTrials.gov

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

May 31, 2011

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG

eltrombopag

eltrombopag tablets daily, in increasing dosage, for three months

DRUG

corticosteroids (Aprednislon)

corticosteroids in decreasing dosage

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Ingrid Pabinger, MD

OTHER

NCT00888901 - Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag | Biotech Hunter | Biotech Hunter